Fig. 3: Rates of pathologic complete response (pCR) among patients with early-stage HER2-positive breast cancer who received neoadjuvant chemotherapy. | npj Breast Cancer

Fig. 3: Rates of pathologic complete response (pCR) among patients with early-stage HER2-positive breast cancer who received neoadjuvant chemotherapy.

From: Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer

Fig. 3: Rates of pathologic complete response (pCR) among patients with early-stage HER2-positive breast cancer who received neoadjuvant chemotherapy.

a Rates of pathologic complete response (pCR) among patients with HER2-positive breast cancer who underwent neoadjuvant chemotherapy according to hormone receptor status. b Rates of pathologic complete response (pCR) among patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy according to race and ethnicity, hormone receptor status and clinical stage.

Back to article page